Durvalumab (Imfinzi®) is indicated for for the treatment of locally advanced, unresectable Non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)1.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||29/03/2019|
|Rapid review completed||29/04/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care.|